Skip to content

Efficacy of Low Frequency Deep Brain Stimulation in Improving Quality of Life in Parkinson's Disease

The Difference Clinical Efficacy of High Frequency and Low Frequency Deep Brain Stimulation in the Treatment of Sleep Disorders of Parkinson's disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044491
Enrollment
Unknown
Registered
2021-03-23
Start date
2021-03-31
Completion date
Unknown
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

HFS-DBS group: HFS-DBS
LFS-DBS group:LFS-DBS

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 55-75 years. 2. Diagnosis is consistent with primary Parkinson's disease. 3. There is a clinically captured typical freezing of gait performance, and after the discussion of clinical experts, it is clearly freezing of gait, instead of gait disorder caused by other factors (video as evidence). 4. No severe tremor (UPDRS-II scale score 16th item = 30%.

Exclusion criteria

Exclusion criteria: 1. The patient refuses to participate in the study and is unwilling or unable to sign the informed consent form. 2. There are mental, psychological, and cognitive impairments that cannot cooperate with surgery and follow-up. 3. Can not walk, or accompanied by other diseases affecting walking distance. 4. There are contraindications for neurosurgery, such as cerebral infarction, hydrocephalus, coagulopathy, etc. 5. There are tumors, liver function, severe renal function abnormalities (index more than 3 times normal) and other concomitant diseases that seriously affect health. 6. There are other neurological lesions, such as intracranial space, cerebrovascular disease, mental illness, etc. 7. Patients cannot be scanned for MRI (such as claustrophobia or implants in the body).

Design outcomes

Primary

MeasureTime frame
PDQ-39;

Secondary

MeasureTime frame
MDS-UPDRS-I;MDS-UPDRS-II;NMSS;HAMA;HAMD;

Countries

China

Contacts

Public ContactZhang Jianguo

Beijing Tiantan Hospital, Capital Medical University

zjguo73@126.com+86 13601294613

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026